SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000929638-24-000901
Filing Date
2024-03-05
Accepted
2024-03-05 16:30:45
Documents
16
Period of Report
2024-03-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 a8k.htm   iXBRL 8-K 34040
2 exhibit10-1.htm EX-10.1 184038
3 exhibit10-2.htm EX-10.2 96885
  Complete submission text file 0000929638-24-000901.txt   508029

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA adxs-20240301.xsd EX-101.SCH 3857
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE adxs-20240301_lab.xml EX-101.LAB 20567
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE adxs-20240301_pre.xml EX-101.PRE 14630
17 EXTRACTED XBRL INSTANCE DOCUMENT a8k_htm.xml XML 3774
Mailing Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852
Business Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852 732 545 1590
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001100397 (see all company filings)

IRS No.: 841521955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36138 | Film No.: 24721063
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)